Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2845400A - Treatment and prevention of immune rejection reactions - Google Patents
[go: Go Back, main page]

AU2845400A - Treatment and prevention of immune rejection reactions - Google Patents

Treatment and prevention of immune rejection reactions

Info

Publication number
AU2845400A
AU2845400A AU28454/00A AU2845400A AU2845400A AU 2845400 A AU2845400 A AU 2845400A AU 28454/00 A AU28454/00 A AU 28454/00A AU 2845400 A AU2845400 A AU 2845400A AU 2845400 A AU2845400 A AU 2845400A
Authority
AU
Australia
Prior art keywords
prevention
treatment
immune rejection
rejection reactions
reactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28454/00A
Inventor
Richard L Franklin
Yves St-Pierre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phairson Medical Inc
Original Assignee
Phairson Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phairson Medical Inc filed Critical Phairson Medical Inc
Publication of AU2845400A publication Critical patent/AU2845400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU28454/00A 1998-12-24 1999-12-23 Treatment and prevention of immune rejection reactions Abandoned AU2845400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11414798P 1998-12-24 1998-12-24
US60114147 1998-12-24
PCT/US1999/030818 WO2000038708A1 (en) 1998-12-24 1999-12-23 Treatment and prevention of immune rejection reactions

Publications (1)

Publication Number Publication Date
AU2845400A true AU2845400A (en) 2000-07-31

Family

ID=22353616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28454/00A Abandoned AU2845400A (en) 1998-12-24 1999-12-23 Treatment and prevention of immune rejection reactions

Country Status (2)

Country Link
AU (1) AU2845400A (en)
WO (1) WO2000038708A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
ATE375717T1 (en) * 1999-02-18 2007-11-15 Denise L Faustman METHOD FOR INHIBITING TRANSPLANT REJECTION
JP2003502071A (en) * 1999-06-18 2003-01-21 ブジャーナソン・ヨーン・ブラーギ Fish serine proteinases and their use in medicines and cosmetics
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
PL2144618T5 (en) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bioeffective krill oil compositions
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
ES2937960T5 (en) 2015-02-11 2026-02-16 Aker Biomarine Human Ingredients As Lipid extraction processes
EP3256553A2 (en) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipid compositions
KR102693802B1 (en) * 2016-02-15 2024-08-08 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. Prevention of graft rejection by prior use of modified grafts
EP4638684A1 (en) * 2022-12-21 2025-10-29 Novozymes A/S Recombinant protease for cell detachment
CN116396932B (en) * 2023-06-07 2023-08-29 上海精翰生物科技有限公司 A blood cell pretreatment composition and its application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
ES2143553T3 (en) * 1993-09-02 2000-05-16 Dartmouth College ANTI-GP39 ANTIBODIES AND THEIR UTILIZATIONS.
WO1998038319A1 (en) * 1997-02-25 1998-09-03 Cortecs (Uk) Limited Component of bromelain

Also Published As

Publication number Publication date
WO2000038708A1 (en) 2000-07-06
WO2000038708A9 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
IL119747A0 (en) Treatment of vegetables
PL335160A1 (en) Treatment of hiv and carcinoma
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU2845400A (en) Treatment and prevention of immune rejection reactions
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
AU1556497A (en) Agents for the treatment and prevention of aids
IL138692A0 (en) Treatment and prevention of vascular disease
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
GB9811598D0 (en) Diagnosis and treatment of cancer
GB9911772D0 (en) Diagnosis and treatment of atherosclerosis
AU1293400A (en) Enzymatic treatment and prevention of hypertrophic skin
AU2964199A (en) Prevention and treatment of adhesions
AU4604697A (en) Compositions and methods for the treatment of human cytomegalovirus infection
EP0644221A3 (en) Preparation and processing of polydiorganosiloxanes.
AU2750297A (en) Methods for prevention and/or treatment of neutropenia
AU3762397A (en) Treatment and prevention of helicobacter infection
AU8968598A (en) Bovine footrot treatment and prevention
AU4107797A (en) Compounds for the treatment and prevention of diabetes
GB9711848D0 (en) Treatment and prophylaxis of infraction
AU1960100A (en) Method of preventing immune and hypersensitivity reactions
AU3735900A (en) Methods of treatment and prevention of restenosis
AU1389897A (en) Use of chemokines for the treatment and prevention of hiv infection
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
AU4556899A (en) Prevention and treatment of sepsis
AU4799797A (en) Antitumor compositions and methods of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase